CTCE 9908 acetate
產(chǎn)品名稱:CTCE 9908 acetate
產(chǎn)品描述:
產(chǎn)品描述 | CTCE 9908 acetate is an antagonist of CXCR4 and inhibits migration in CXCR4-expressing ovarian cancer cells. |
體外活性 | CTCE 9908 acetate inhibited ovarian cancer cell migration to CXCL12, but on longer incubation, caused cell death in CXCR4-positive cells. CTCE 9908 acetate did not cause apoptosis or cellular senescence, but induced multinucleation, G(2)-M arrest, and abnormal mitosis in ovarian cancer cells. CTCE 9908 acetate deregulated DNA damage checkpoint proteins and spindle assembly checkpoint proteins at G(2)-M phases of the cell cycle. Combination treatment of CTCE 9908 acetate and the drug paclitaxel led to an additive cytotoxicity that also involved mitotic catastrophe[1]. |
體內(nèi)活性 | In dosing experiment of CTCE 9908 acetate in the PyMT mouse model, increasing doses of CTCE 9908 acetate alone slowed the rate of tumor growth, with a 45% inhibition of primary tumor growth at 3.5 weeks of treatment with 50 mg/kg of CTCE 9908 acetate (p = 0.005). Expression levels of VEGF were also found to be reduced by 42% with CTCE 9908 acetate (p = 0.01). In combination with docetaxel, CTCE 9908 acetate administration decreased tumor volume by 38% (p = 0.02), an effect that was greater than that observed with docetaxel alone. In combination with DC101, CTCE 9908 acetate also demonstrated an enhanced effect compared to DC101 alone, with a 37% decrease in primary tumor volume (p = 0.01) and a 75% reduction in distant metastasis (p = 0.009). In combination with docetaxel or an anti-angiogenic agent, the anti-tumor and anti-metastatic effects of CTCE 9908 acetate were markedly enhanced[2]. |
分子量 | 1987.31 |
分子式 | C88H151N27O25 |
聯(lián)系我們:
郵箱:2519696869@qq.com
QQ: 2519696869
電話:18066853083
微信:18066853083

公司介紹:
西安齊岳生物科技有限公司是集化學科研和定制與一體的高科技化學公司。業(yè)務范圍包括化學試劑和產(chǎn)品的研發(fā)、生產(chǎn)、銷售等。涉及產(chǎn)品為通用試劑的分銷、非通用試劑的定制與研發(fā),涵蓋生物科技、化學品、中間體和化工材料等領域。
主營產(chǎn)品:COF、MOF單體系列:三蝶烯衍生物、金剛烷衍生物、四苯甲烷衍生物、peg、上轉換、石墨烯、光電材料、點擊化學、凝集素、載玻片、蛋白質交聯(lián)劑、脂質體、蛋白、多肽、氨基酸、糖化學等。